Latest Conference Articles

September 7th 2025, 12:25am

IASLC World Conference on Lung Cancer

Perioperative nivolumab maintained HRQOL and decreased the risk of deterioration vs placebo in patients with stage III N2 NSCLC.

September 6th 2025, 9:48pm

IASLC World Conference on Lung Cancer

COMPEL data support osimertinib plus chemotherapy in EGFR-mutated NSCLC after non-CNS progression on frontline osimertinib.

September 6th 2025, 8:03pm

IASLC World Conference on Lung Cancer

First-line iza-bren plus osimertinib demonstrated a manageable safety profile with preliminary antitumor activity in EGFR-mutant NSCLC.

September 6th 2025, 5:02pm

Society of Hematologic Oncology Annual Meeting (SOHO)

A chemotherapy-free regimen of mosunetuzumab and polatuzumab vedotin improved PFS and response rates vs R-GemOx in relapsed/refractory LBCL.

September 6th 2025, 4:55pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Treatment with mosunetuzumab plus polatuzumab vedotin yielded high response rates and had a manageable safety profile in BTK inhibitor–exposed MCL.

September 6th 2025, 4:30pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Loncastuximab tesirine plus glofitamab demonstrated early promise in patients with relapsed or refractory large B-cell lymphoma.

September 6th 2025, 3:42pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Ghayas C. Issa, MD, MS, discusses the optimal timing of and approaches to genetic testing for NPM1 and KMT2A alterations in AML.

September 5th 2025, 10:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Frontline treatment with mosunetuzumab showed high antitumor activity in patients with marginal zone lymphoma regardless of risk status.

September 5th 2025, 6:43pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Treatment with an investigational allogeneic T-cell immunotherapy improved outcomes vs conventional transplant in patients with hematologic malignancies

September 5th 2025, 4:19pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Sanam Loghavi, MD, discusses standard-of-care frontline testing in myelodysplastic syndrome.

September 5th 2025, 3:02pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Subcutaneous daratumumab monotherapy demonstrated a 24-month PFS rate of 79.9% in patients with high-risk smoldering multiple myeloma.

September 5th 2025, 1:49pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Sundar Jagannath, MBBS, explores how minimal residual disease could redefine what it means to achieve a "cure" in multiple myeloma.

September 5th 2025, 1:39pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Francesca Palandri, MD, discusses research needed to clarify the role of predictive markers for ruxolitinib response in myelofibrosis.

September 4th 2025, 9:30pm

Bridging the Gaps in Lung Cancer

Narjust Florez, MD, discusses the publication of a consensus manuscript in Cancer on recommendations for clinical strategies for lung cancer management.

September 4th 2025, 9:08pm

Society of Hematologic Oncology Annual Meeting (SOHO)

The combination of ziftomenib and cytarabine/daunorubicin showed a manageable safety profile with early efficacy in NPM1-mutated and KMT2A-rearranged AML.

September 4th 2025, 8:15pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Favorable long-term outcomes were reported with brexu-cel in patients with B-ALL and low disease burden who achieved peak CAR T-cell expansion.

September 4th 2025, 7:21pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Zanubrutinib bested acalabrutinib plus venetoclax in terms of PFS in patients with treatment-naive, low-risk CLL.

September 4th 2025, 6:45pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Findings from a meta-analysis associated asciminib with improved efficacy and safety vs other TKIs in chronic myeloid leukemia.

September 4th 2025, 6:00pm

Society of Hematologic Oncology Annual Meeting (SOHO)

First-line venetoclax plus azacitidine did not improve overall survival vs placebo plus azacitidine in treatment-naive, higher-risk MDS.

September 4th 2025, 5:10pm

Society of Hematologic Oncology Annual Meeting (SOHO)

Continuous zanubrutinib improved PFS and showed a trend for improved OS vs fixed-duration venetoclax-based therapy in treatment-naive CLL/SLL.